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Abstract 
Background: Drugs such as taxanes, epothilones, and vinca alkaloids are widely used in the treatment of breast, 
ovarian, and lung cancers but come with major side effects such as neuropathy and loss of neutrophils and as single 
agents have a lack of efficacy. M2I‑1 (MAD2 inhibitor‑1) has been shown to disrupt the CDC20‑MAD2 interaction, and 
consequently, the assembly of the mitotic checkpoint complex (MCC).
Results: We report here that M2I‑1 can significantly increase the sensitivity of several cancer cell lines to anti‑mitotic 
drugs, with cell death occurring after a prolonged mitotic arrest. In the presence of nocodazole or taxol combined 
with M2I‑1 cell death is triggered by the premature degradation of Cyclin B1, the perturbation of the microtubule net‑
work, and an increase in the level of the pro‑apoptotic protein MCL‑1s combined with a marginal increase in the level 
of NOXA. The elevated level of MCL‑1s and the marginally increased NOXA antagonized the increased level of MCL‑1, 
a pro‑survival protein of the Bcl‑2 family.
Conclusion: Our results provide some important molecular mechanisms for understanding the relationship between 
the mitotic checkpoint and programmed cell death and demonstrate that M2I‑1 exhibits antitumor activity in the 
presence of current anti‑mitotic drugs such as taxol and nocodazole and has the potential to be developed as an 
anticancer agent.
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Background
The spindle assembly or mitotic checkpoint (SAC) moni-
tors the microtubule and kinetochore attachments to 
prevent a premature metaphase to anaphase transition 
and therefore helps to maintain genomic stability [1–4]. 
The SAC can sense any unattached kinetochores and 
responds by producing diffusible signals which inhibit 
the activity of the anaphase-promoting complex or cyclo-
some (APC/C) [3]. The APC/C acts as an E3 ligase and 
is essential for ubiquitin-mediated degradation of target 
proteins [1, 4–6]. Cyclin B1 is an important substrate of 
the APC/C and plays a critical role in facilitating mitotic 
entry and exit by regulating Cdk1 kinase activity [7, 8]. 
The MCC (Mitotic checkpoint complex) is believed to be 
one of the most prominent SAC inhibitory signals and 
consists of four components, CDC20, MAD2, BUBR1, 
and BUB3 [5, 9, 10]. It is assembled from the two sub-
complexes, CDC20-MAD2 and BUBR1-BUB3 [10, 
11]. The evidence suggests that as well as forming dur-
ing prometaphase and metaphase in response to unat-
tached kinetochores, the CDC20-MAD2 sub-complex 
can also be formed in prophase before nuclear envelope 
breakdown [6, 12, 13]. This prophase associated and SAC 
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independent CDC20-MAD2 complex prevents the pre-
mature degradation of Cyclin B1 before the cell enters 
mitosis [6, 13].
Cells with depleted or down-regulated Cyclin B1 often 
undergo apoptosis [14, 15]. Many of the SAC compo-
nents are essential, and abnormal up- or down-regulation 
of its activity often results in cells experiencing a pro-
longed mitotic arrest or prematurely exiting mitosis [3, 
16]. This in turn might lead to tumorigenesis, but most 
of the cells will commit suicide by entering programmed 
cell death [17–19]. One consequence of this mitotic 
vulnerability has been the development of anti-mitotic 
drugs for cancer therapy [20–23]. In fact, traditional 
anti-mitotic drugs, such as taxanes, epothilones, and 
vinca alkaloids are widely used and have been proven to 
be successful in the clinical treatment of breast, ovarian, 
and lung cancers [24, 25]. However, because they target 
microtubules they lack specificity, which results in side 
effects such as peripheral neuropathy and rapid develop-
ment of resistance, and as single agents they show a lack 
of efficacy [23, 26].
Blocking mitotic exit is an efficient way of inducing 
tumor cell death, so in principle, compounds that directly 
target the APC/C or MCC to cause cells to arrest in 
mitosis should be more efficacious and have no or fewer 
side effects. M2I-1 (MAD2 inhibitor-1) is the first small 
molecule that has been identified as an inhibitor of the 
CDC20-MAD2 interaction, which is an essential process 
in the assembly of the MCC and the inhibition of the 
APC/C [6, 27]. Here we report the discovery that M2I-1 
enhances the sensitivity of cancer cell lines to anti-mitotic 
drugs which might be of use in antitumor therapy.
Results
M2I‑1 promotes the sensitivity of cancer cell lines 
to anti‑mitotic drugs
In HeLa cells a normal cell cycle lasts about 20  h with 
mitosis taking about 1 h [28], and the daughter cells then 
rapidly entering the next cell cycle. Nocodazole (NOC) 
is a microtubule poison, which causes depolymerisation 
of the microtubules and activation of the SAC to arrest 
the cell at prometaphase [29] and HeLa cells can toler-
ate treatment with 40–400  ng/ml nocodazole for up 
to 24  h with no significant DNA damage or cell death 
[30, 31], though, a prolonged mitotic arrest (> 24  h) 
can cause apoptosis [17, 29]. However, we have noticed 
that when HeLa cells were treated for 16  h with 60  ng/
ml nocodazole combined with 50  μM M2I-1 (hereafter 
‘NOC + M2I-1’), there was a significant (16.4%) increase 
in cell death compared to cells treated with 60  ng/ml 
nocodazole or 50  μM M2I-1 alone (Fig.  1b). The dead 
cells were identified by their fragmented cell body, which 
in many cases looks like a typical apoptotic-body (Fig. 1a, 
asterisk) [32, 33].
There is no significant difference in the number of cell 
deaths seen in cells treated with 0.5% DMSO (control), 
and either 50  μM M2I-1 or 60  ng/ml nocodazole alone 
(Fig. 1b). There is no significant difference in the mitotic 
index between the DMSO control and M2I-1 treated cells 
and as expected, about 80% of cells were arrested in mito-
sis in response to nocodazole treatment (Fig. 1c). In con-
trast, however, cells treated with NOC + M2I-1 showed 
a significant (18.9%) reduction in the mitotic index com-
pared to cells treated with nocodazole alone (Fig.  1c). 
This increase in cell death has also been observed in cells 
treated with Taxol combined with M2I-1 (Fig. 1d, e). To 
test if this is unique to HeLa cells, various apoptotic-
sensitive cell lines, HT-29, A549, U2OS were examined 
under the same conditions. Results showed that treat-
ment with NOC + M2I-1 increased the rate of cell death 
by a varying amount in all cases (Fig. 1f ). Thus it appears 
that M2I-1 can potentiate the sensitivity of some cancer 
cells to anti-mitotic drugs like nocodazole and taxol.
The beginning of cell death occurred after prolonged 
mitotic arrest
Why M2I-1 in the presence of nocodazole should induce 
cell death is intriguing, as this contradicts what would 
be anticipated based on the original observations that 
M2I-1 disrupted the interaction between CDC20 and 
MAD2 and caused a weak SAC [6, 27]. We had antici-
pated that, at least initially, we would see less cell death 
Fig. 1 M2I‑1 promotes the sensitivity of cancer cell lines to anti‑mitotic drugs. HeLa cells were treated with one of 0.5% DMSO, 50 μM M2I‑1, 
60 ng/ml nocodazole, or 60 ng/ml nocodazole + 50 μM M2I‑1 in a 24‑well plate for 16 h. Digital images of cells from three or four random areas of 
each well were taken using a digital camera mounted on a tissue culture microscope with a 20x objective lens and used to quantify the mitotic 
and apoptotic indices. a Sample images showing non‑mitotic cells (arrows), normal mitotic cells (arrowheads), mitotically arrested cells (dash line 
arrows), and apoptotic cells (asterisk). b, d Apoptotic indices quantified from HeLa cells treated with 60 ng/ml (equivalent to 200 nM) nocodazole or 
30 nM Taxol under different circumstances as indicated. c, e Mitotic indices quantified from HeLa cells treated with 60 ng/ml nocodazole or 30 nM 
Taxol under the circumstances indicated. f Apoptotic indices quantified from A549, HT‑29 and U2OS cells under the same conditions as described 
above. All the quantitative data were produced from four independent experiments. n, total cell numbers used for quantification; Noc, nocodazole; 
M2I‑1, MAD2 inhibitor‑1. P value: *< 0.017; **< 0.001; ***< 0.0003; ****< 0.0001
(See figure on next page.)
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when the cells were treated with NOC + M2I-1 due to 
the weakened SAC leading to more slippage, and this 
was supported by the observations that there was a 
reduced mitotic index, and 15% lower level of histone 
H3 S-10 phosphorylation in samples treated with the 
NOC + M2I-1 compared to samples treated with noco-
dazole alone (Figs. 1c, 2a, b). As the observed cell death 
might be caused at some stage of the next cycle after 
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slippage, live images of a HeLa cell line over-expressing 
a Histone 2B-GFP fusion protein were recorded for 24 h 
using a Nikon A1R fully automated high-speed confocal 
imaging system under conditions described previously 
[6]. The Histone 2B-GFP signals were used to visualise 
the chromosomal morphology, which determines the cell 
cycle stage and chromosomal status; DIC images were 
used to reveal the morphological changes in the cytoplas-
mic membrane (Fig. 2c, normal cell cycle).
Cells were seen to round up with condensed chro-
mosomes as they arrested at prometaphase-like states 
in response to the nocodazole treatment (Fig.  2d white 
arrowheads). The beginning of cell death was defined as 
a cell starting to show blebbing of its cytoplasmic mem-
brane (Fig.  2d, diamond heads)  or to display shrinkage 
of the cell body (Fig.  2e, black arrowheads). This was 
followed by the production of overcondensed chromo-
somes (Fig. 2d, e, white dash line arrows) or breaking of 
the chromosomes (Fig. 2d, e, white solid arrows), and the 
formation of a typical late stage apoptotic body (Fig. 2d, 
e, white asterisks) [34]. The slippage of a cell was deter-
mined by the decondensation of the prometaphase-like 
arrested chromosomes with no cytoplasmic division 
(Fig.  3a, arrows) and the regaining of their cytoplasmic 
membrane attachment (Fig. 3a, dash line arrows) [29].
The quantification of the mitotic and cell death indices 
using this histone 2B-GFP line (Fig. 3b, c) shows similar 
patterns to the previous observations (Fig. 1). There were 
significant increases in the cell death after 16 and 24 h of 
treatment with NOC + M2I-1 compared to nocodazole 
alone (Fig.  3b). In a separate experiment, we examined 
the mitotic index and apoptotic index at 24, 36 and 48 h 
(Fig. 3d, e). As expected the number of cells arrested in 
mitosis gradually reduced after 24  h (Fig.  3d), and this 
was correlated with the increased cell death (Fig.  3e), 
however, the amount of cell death induced by the pres-
ence of NOC + M2I-1 is significantly higher at each time 
point compared to that induced by nocodazole alone 
(Fig. 3e).
Given that M2I-1 induces the premature degradation 
of Cyclin B1 in the presence of nocodazole [6], then if 
the Cyclin B1 levels continue to decrease after prolonged 
mitotic arrest, more cells might undergo mitotic exit 
and escape mitotic cell death. Surprisingly though, slip-
page could rarely be identified in cells treated either with 
nocodazole alone or NOC + M2I-1 within the entire 24 h 
recording time, and whilst there was a slight increase in 
slippage events after 48  h of treatment, there were no 
significant differences observed between these two treat-
ments (Fig.  3f ). Instead, cell death was induced within 
the same cell cycle, and the majority of these cells begin 
to die after 16  h of mitotic arrest (Fig.  2d). Therefore, 
the reduced levels of histone H3 S-10 phosphorylation 
in samples treated with the NOC + M2I-1 compared to 
samples treated with nocodazole alone was a conse-
quence of the reduced mitotic cell population caused by 
cell death (Figs. 1c, 2a, b). A small proportion (~ 5%) of 
these dead cells entered the cell death programme with 
a prophase-like morphology (Fig. 2e). These cells devel-
oped severe chromosomal degeneration or fragmentation 
first (Fig. 2e, dash line arrows) and displayed less blebbing 
of the cytoplasmic membrane (Fig. 2e black arrows). The 
typical apoptotic body-like morphology was only formed 
at a very late stage in the process (Fig. 2e white asterisk).
M2I‑1 induced caspase‑3 cleavage in the presence 
of nocodazole
As the majority of the cells that died after a prolonged 
arrest showed typical apoptotic morphology, we exam-
ined caspase-3 cleavage to confirm that the apoptotic 
pathway had contributed to their cell death. The results 
showed that the cleavage of caspase-3 remained very low 
or undetectable in both the control samples treated with 
0.5% DMSO and the samples treated with 50 μM M2I-1 
(See figure on next page.)
Fig. 2 The majority of cell deaths occurred after prolonged mitotic arrest. a Cell extracts were prepared from HeLa cells after 16 h of the different 
drug treatments as described previously. The western blot membranes were probed with a rabbit polyclonal anti‑phospho‑histone H3 (S‑10) 
antibody (Millipore, #06‑570) (1:500 dilutions), and the actin protein bands acted as the loading control. b Quantitative comparison of the 
phospho‑histone 3 S‑10 bands. Results produced from three independent experiments. c The confocal time‑lapse images showing an example of 
a normal/unperturbed HeLa H2B‑GFP cell undergoing the cell cycle in mitosis. d An example of a HeLa H2B‑GFP cell undergoing apoptosis after 
prolonged mitotic arrest by 60 ng/ml nocodazole or 60 ng/ml nocodazole + 50 μM M2I‑1. The white arrowhead indicates the time point when the 
cytoplasmic membrane (DIC grey images) of the cell starts shrinking and rounding up with condensed chromosomes (green). The diamond heads 
indicate the time point that the cytoplasmic membrane began blebbing. The chromosomes displaying fragmentation and over‑condensation are 
highlighted by white dashed arrows and normal arrows respectively. A typical apoptotic‑body like morphology is highlighted with the asterisk. e 
An example of a HeLa H2B‑GFP cell undergoing apoptosis at a prophase‑like stage induced by treatment with 60 ng/ml nocodazole + 50 μM M2I‑1. 
The white arrowhead highlights the time point where there is clear cell body shrinkage, dash arrows highlight the fragmenting chromosomes and 
normal black arrows indicate the intact cytoplasmic membrane during chromosome fragmentation. Asterisks highlight the formation of a typical 
apoptotic‑body like morphology. The green histone 2B‑GFP highlights the chromosomal morphologies and the DIC images in grey indicate the 
cellular boundaries and the cytoplasmic membrane. The timing of the images is indicated
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alone (Fig. 4a, lanes 1 and 2). Samples prepared from cells 
treated with 60 ng/ml of nocodazole alone showed some 
cleavage of caspase-3 (Fig. 4a, lane 3 and b), and the level 
from cells treated with NOC + M2I-1 was significantly 
higher (Fig. 4a, lane 4 and b). Thus, the cell death induced 
by M2I-1 in the presence of nocodazole is associated 
with the caspase-3 dependent apoptotic pathway.
a b
c
d
e
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Fig. 3 The comparison of the amount of slippage and mitotic status of the HeLa cells caused by the various drug treatments. The cells used are 
the same cells as for Fig. 2. a An example of confocal time‑lapse images showing a HeLa H2B‑GFP cell undergoing slippage. The white arrows 
indicate the chromosomes that are undergoing premature decondensation without cytokinesis having taken place. The white dash line arrows 
highlight the re‑attachment of the cytoplasmic membrane. b The quantitative cell death that occurred after prolonged mitotic arrest from cells 
treated with 60 ng/ml nocodazole alone (grey border) or 60 ng/ml nocodazole + 50 μM M2I‑1 treatment (black border). The results were produced 
from three independent experiments. *P value: < 0.012, **P value < 0.002. c Quantitative results showing the mitotic indices due to the different 
drug treatments (color‑coded as above) at different time intervals. **P value < 0.002. d Quantitative results showing the mitotic indices due to the 
different drug treatments (black/grey borders the same as above) at different time intervals as indicated. P values shown as indicated. e Quantitative 
results showing the apoptotic indices due to the different drug treatments (color‑coded the same as above) at different time intervals as indicated. 
P values shown as indicated. f Quantitative results comparing the slippage rates between different drug treatments (color‑coded same as above). 
The data from three independent experiments were used for the quantifications. n, cell numbers used for quantification; ns, not significant
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The DNA damage checkpoint is less likely to contribute 
to this specific cell death
To examine if these cell deaths could be caused by DNA 
damage, we analysed the formation of γ-H2AX foci (a 
newly phosphorylated histone 2AX, H2A histone fam-
ily member X), a typical indicator of DNA double-strand 
breaks [35] and used VP16 (etoposide) as a positive con-
trol as it is known to induce DNA damage [36]. The per-
centage of cells containing more than five γ-H2AX foci 
from un-arrested cells at the cell cycle stage similar to 
the cells treated with VP16, indicated by the morphology 
of their DAPI staining, has been used to represent the 
DNA damage level at each time point [37]. After 16 h of 
treatment with either NOC or NOC + M2I-1 there were 
insufficient numbers of un-arrested cells for quantifica-
tion, so we have compared the average fluorescent inten-
sities of the γ-H2AX foci from the mitotically arrested 
cells despite the fact that DNA-PKcs/CHK2 can also 
increase the level of γ-H2AX in mitotically arrested HeLa 
cells in the absence of DNA damage [37]. We anticipated 
that if there were additional DNA damage caused by the 
M2I-1 in the presence of nocodazole, we would see a 
higher level of γ-H2AX. The confocal images (Fig. 5a) and 
the quantitative results (Fig. 5b) showed that cells treated 
with nocodazole alone or NOC + M2I-1 have slightly 
more γ-H2AX foci compared to the DMSO negative con-
trol and this suggests that some DNA damage occurred 
under these two conditions. However, these levels of 
DNA damage were rather weak when compared to the 
levels seen in the positive control which was cells treated 
with VP16 for only 2  h (Fig.  5a, b). More importantly, 
there is no significant difference in this small amount of 
DNA damage at each time point examined. All of which 
suggests that the DNA damage pathway is not involved 
in the cell death induced by M2I-1 in the presence of 
nocodazole.
M2I‑1 in the presence of nocodazole induced 
the down‑regulation of Cyclin B1
Cyclin B1 is the regulatory subunit of Cdk1, and its level 
is regulated by the anaphase-promoting complex or 
cyclosome (APC/C) [2, 38]. Under certain circumstances 
Cyclin B1 has been regarded as an essential molecule 
in the determination of tumor cell fates [14, 34]. Previ-
ously it has been shown that targeting Cyclin B1 inhibits 
proliferation and sensitizes cancer cells to taxol [14, 15], 
and that apoptosis induced by drugs is often accompa-
nied by the down-regulation of Cyclin B1 [14, 39]. To test 
if M2I-1 could prevent the accumulation of Cyclin B1, 
HeLa cells were treated as described before for 16 h and 
then fixed and antibody stained using the PLA method 
described previously [6] (Fig. 6a). The samples made from 
cells treated with M2I-1 showed significantly reduced 
amounts of Cyclin B1 in prophase or mitosis compared 
to control cells (Fig.  6a), and this was confirmed by the 
quantitative results (Fig.  6b). This premature Cyclin B1 
degradation connected with a weakened SAC was con-
firmed by showing that M2I-1 disrupted the in vivo inter-
action between CDC20 and MAD2 in mitotic HeLa cells 
[6]. This was further supported by the observation of an 
overall reduction in Cyclin B1 detected by western blot 
(Fig. 8a lane 2 and 4).
The role of “competing‑networks” cannot apply to the cell 
death induced by M2I‑1 in the presence of nocodazole
MCL-1 (myeloid cell leukemia 1) is a pro-survival mem-
ber of the Bcl-2 family of proteins [40]. It prevents the 
oligomerisation of the pro-apoptotic proteins Bak and 
Bax on the mitochondrial membrane, and so, stops the 
release of cytochrome C thus avoiding the activation 
of caspase [40, 41]. In unperturbed normal HeLa cells 
the expression of MCL-1 is cell cycle regulated, its lev-
els increase during mitosis and peak around metaphase 
and early anaphase, but remained low in interphase 
a
b
Fig. 4 M2I‑1 induced caspase‑3 activity in the presence of 
nocodazole. a Cell extracts were prepared from HeLa cells under 
different drug treatments as indicated. 60 µg/lane of total protein 
from each sample was loaded for protein separation using a 10% 
precast SDS‑PAGE tris‑bis protein gel, and after western blotting the 
membranes were probed with an anti‑caspase‑3 antibody (Abcam, 
ab32351, 1:1000 dilutions), an anti‑GAPDH antibody (Thermo 
Fisher Scientific, MA5‑15738, 1:1000 dilutions) which acted as the 
loading control. Lane 1: HeLa cells treated with 0.5%DMSO (v/v) as 
control; lane 2: Cells treated with 50 µM M2I‑1; lane 3: Cells treated 
with 60 ng/ml nocodazole; and lane 4: Cells treated with 60 ng/ml 
nocodazole + 50 µM M2I‑1 for 24 h. b Quantitative results comparing 
the cleaved form of the caspase‑3 from western blots of three 
independent experiments. P value ** < 0.0026
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(Fig. 7a). In response to the nocodazole provoked SAC it 
is degraded (Fig. 7b bottom panel) and that degradation 
can be prevented by MG132 (Fig. 7b bottom panel).
The degradation of MCL-1 is associated with the trig-
gering of apoptosis in many different types of cells [42, 
43] and its phosphorylation by Cyclin B1-dependent 
Cdk1 kinase facilitates this degradation [44]. It has been 
suggested that the accumulation of Cyclin B1 caused by 
an active SAC facilitates the degradation of MCL-1 to 
promote apoptosis, and vice versa [45]. A more recently 
proposed “competing-networks” model suggests that the 
rise of an as yet undefined death signal competes with the 
survival signal generated by the reduction of Cyclin B1 
to determine whether the cell dies in mitosis or exits and 
returns to interphase [20, 34].
We, therefore, examined the protein profiles of Cyc-
lin B1 and MCL-1 from the samples described above 
(Fig. 8a). As expected, when Cyclin B1 was stabilized by 
the treatment with nocodazole alone, it was associated 
with a significant reduction of MCL-1 (Fig. 8a, lane 3), 
and the lowered Cyclin B1 induced by the combined 
drugs, is associated with an elevated MCL-1 (Fig.  8a, 
lane 4). This is a surprise when the cell death observed 
previously (Fig.  1b, d) is also considered. The levels 
of the pro-apoptotic proteins BIM, BID, and PUMA 
remained relatively unchanged or even slightly reduced 
(Fig.  8b–d), but the level of NOXA increased mar-
ginally (Fig.  8f lane 4). However, the levels of an anti-
survival protein, MCL-1s (a short form variant of the 
full-length MCL-1 which acts to sequester the function 
of MCL-1), increased when the cells were treated with 
NOC + M2I-1 compared to nocodazole alone (Fig.  8a 
lane 4 and e lane 4). Therefore, the increased levels of 
the pro-apoptotic proteins MCL-1s and NOXA might 
antagonize the increased level of MCL-1. In order to 
test this speculation, live-cell images were recorded 
examining the behaviour of a cell line (MCF-7) which 
lacks the expression of MCL-1s [46], in response to 
prolonged mitotic arrest in the presence of nocodazole 
and M2I-1 or nocodazole alone. The experiment was 
conducted using the same conditions as described in 
Fig.  2 apart from determination of the chromosomal 
morphologies which was illustrated by staining with 
0.2  μM SiR-DNA (Tebu-Bio, UK) [47]. As with HeLa 
cells, the mitotic index began to reduce in the group 
treated with both drugs after 16  h of incubation, and 
this became significant at 20  h compared to the cells 
treated with nocodazole alone (Fig.  8g). However, in 
contrast to HeLa cells, M2I-1 failed to induce cell death 
in the presence of nocodazole in MCF-7 cells over 
the time course of the observations (Fig.  8h), and the 
reduced mitotic index in MCF-7 cells after double drug 
treatment is caused by cell slippage (Fig. 8i). As MCL-
1s is a short form and the consequence of an alterna-
tive splicing event of the full length MCL-1 pre-mRNA 
[48, 49], it is impossible to design siRNA experiments 
a
b
Fig. 5 The comparison of the γ‑H2AX foci formation profiles under 
the different drug treatment conditions. a Representative confocal 
images showing the γ‑H2AX foci formed in HeLa cells at different 
cell cycle stages. Arrows indicate a metaphase cell treated with 
0.5% DMSO for 2 h (negative control), or a prometaphase‑like cell 
from those treated with 60 ng/ml nocodazole (NOC) alone, and 
60 ng/ml NOC + 50 μM M2I‑1 for 16 h respectively. Cells treated 
with 10 mM VP16 for 2 h act as a positive control. Asterisks highlight 
those un‑arrested cells after NOC and NOC + M2I‑1 treatment or 
ones from the negative control at a similar cell cycle stage to the 
VP16 treated cells as justified by their DNA morphologies. These 
cells were fixed with 4% formamide‑PBS solution and stained with 
a primary anti‑γ‑H2AX antibody (Abcam, ab‑2893, 1:500 dilutions). 
The specific fluorescent signals of the γ‑H2AX foci were illustrated 
by a Cy5 secondary antibody (Abcam, ab6564, 1:500 dilutions) in red 
and were indicated by dash line arrows. DNA was stained with DAPI 
and is shown in blue. b The quantitative results comparing the DNA 
damage levels indicated by the percentage of cells having more 
than 5 γ‑H2AX foci from the cell population being treated at different 
time intervals as indicated. Under a 40x oil objective lens, the cells 
from four or five random areas of the confocal images were taken to 
give the quantitative results. Three independent experiments were 
conducted to produce the data. P value *** < 0.003. NS, not significant
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that directly and specifically target MCL-1s for deple-
tion in HeLa cells, and so we transfected the MCF-7 
cell line with the plasmid DNA of pCMV-AN-mGFP-
MCL-1s so that it would express the exogenous GFP-
MCL-1s protein. These transfected cells (Fig. 9, lane 3 
and 4) along with the normal MCF-7 cells (Fig. 9, lane 
1 and 2) were then treated with the drugs as described 
above, and the samples were prepared for western 
blot analysis. As MCF-7 cells also lack the expression 
of caspase-3 [50, 51], we examined the cleavage of 
PARP-1 (Poly [ADP-ribose] polymerase  1) to evaluate 
the apoptotic activity, as it is a well-established bio-
marker for cell death [52, 53]. The lack of expression 
of the endogenous MCL-1s in these samples (Fig.  9, 
lane 1–4), and the expression of the exogenous GFP-
MCL-1s fusion protein in the transfected MCF-7 cells 
(Fig.  9, lane 3 and 4) were confirmed using a specific 
anti-MCL-1 antibody. The endogenous MCL-1 in these 
MCF-7 cells behaved the same as it had done in the 
HeLa cells. Its levels increased when cells were treated 
with the combined drugs NOC + M2I-1 compared to 
the cells treated with nocodazole alone (Fig. 9a, lanes 2 
a
b
Fig. 6 M2I‑1 induced the down‑regulation of Cyclin B1. a Representative confocal images which show the selected cell cycle stages of early 
prophase (Early Pro), prophase (Pro), prometaphase (ProM), and metaphase (Met) of HeLa cells after treatment with 0.5% DMSO (control) and 50 μM 
M2I‑1 respectively. Fixed and rehydrated slides were treated with anti‑Cyclin B1 antibodies for a PLA assay, after the PLA they were also probed using 
a pericentrin antibody and the DNA stained using DAPI. The cyclin B1 signal is in red (white arrowheads), pericentrin in green, and the DNA stained 
with DAPI in blue. The DNA morphologies and the centrosome status indicated by white arrows (Pericentrin staining) were used for determining 
the cell cycle stages as indicated. The nuclear and cytoplasmic regions are encircled by the dash lines. b Quantitative results comparing the levels of 
cyclin B1 at prophase, or prometaphase and metaphase based on single cell analysis from the cell population gathered from a. P value **** < 0.0001
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and 4 compared to lanes 1 and 3). Similarly, the level of 
exogenous GFP-MCL-1s is also increased in the sample 
treated with the combined drugs (Fig. 9a, lane 4 com-
pared to lane 3). The results show that the level of the 
cleaved PARP-1 increased significantly in the sample 
treated with NOC + M2I-1 compared to the sample 
treated with nocodazole alone in the cells transfected 
with GFP-MCL-1s (Fig. 9a, lane 3 and 4 and b). In con-
trast, only very low levels of PARP-1 and no significant 
difference in its cleavage could be detected from the 
normal MCF-7 cells after treatment with the same con-
ditions as above (Fig. 9a, lanes 1 and 2). Thus, MCL-1s 
is the main factor that antagonizes the elevated level of 
MCL-1 and causes the cell death induced by M2I-1 in 
the presence of nocodazole or taxol.
Discussion
M2I-1 (MAD2 inhibitor-1) is the first small molecule that 
has been identified which disrupts the CDC20-MAD2 
interaction both in vitro and in vivo, an essential process 
in the assembly of the MCC [6, 27]. We have previously 
reported that M2I-1 can prevent the formation of the 
CDC20-MAD2 complex both at prophase before NEBD 
(nuclear envelope break-down) and at prometaphase and 
a
b
Fig. 7 The regulation of the stabilities of MCL‑1, Cyclin A in HeLa cells. a Representative confocal images showing the expressions and 
distributions of the MCL‑1 (green in merged images) in unperturbed HeLa cells at different cell cycle stages as indicated. Cyclin A in red (merged 
images, Santa Cruz, sc‑271682, mouse monoclonal anti‑cyclin A (B‑8) 1:500 dilutions). These cells were fixed with 4% formamide‑PBS solution 
and stained with a primary anti‑Mcl‑1 (S‑19, Santa Cruz, sc‑819) antibody (1:500 dilutions) or anti‑Cyclin A (B‑8) antibody (Santa Cruz, sc‑271682) 
(1:500 dilutions). DNA was stained with DAPI (blue in merged images). The distributions of the fluorescent signals of Cyclin A throughout the cell 
cycle used for timing the cell cycle stages for comparison purpose. b Representative confocal images showing the expressions of MCL‑1 (green) in 
nocodazole arrested (top panel) or nocodazole and MG132 arrested (bottom panel) HeLa cells. DNA was stained with DAPI (blue in merged images) 
and the mitotic status highlighted by staining with the phosphor‑histone H3 S‑10 antibody (red, Cell signalling, 9706, 1:200 dilutions). HeLa cells 
were treated with nocodazole or nocodazole + MG132 for 8 h
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metaphase [6]. We have also found that the disruption 
of the interaction between CDC20 and MAD2 induced 
by the M2I-1 treatment correlated with the premature 
degradation of Cyclin B1 at both stages (Fig.  6a, b) [6]. 
Intriguingly, we show here that M2I-1 could significantly 
increase the sensitivity of several lines of cancer cells to 
anti-mitotic drugs such as nocodazole and taxol both 
within 24  h or beyond (Figs.  1, 3). It has been believed 
that when a cell is in a prolonged mitotic arrest, a gradu-
ally declining level of Cyclin B1 and a stabilised level of 
MCL-1serve as a survival signal which competes with an 
as yet undefined death signal to determine whether the 
a
b
c
d
e
f
g h
i
Fig. 8 The regulation of the stability of MCL‑1, cyclin B1, and other pro‑ or anti‑apoptotic proteins in HeLa and MCF‑7 cells. a Western blots of 
cell extracts prepared from HeLa cells after treatment with 0.5% DMSO, 50 μM M2I‑1, 60 ng/ml nocodazole, and 60 ng/ml nocodazole + 50 μM 
M2I‑1 respectively and probed with a rabbit polyclonal anti‑cyclin B1 antibody (H‑433) antibody (sc‑7520); a mouse monoclonal anti‑actin (AC‑15) 
antibody (ab6276) was used as the loading control. b–f Western blot results showing the expression levels of the pro‑apoptotic proteins BIM, BID, 
PUMA, NOXA, and MCL‑1s in HeLa cells. Cell extracts were prepared from HeLa cells after treatment with nocodazole alone or nocodazole + M2I‑1 
as described before. Actin bands were used as the loading controls. MCF‑7 cells were treated using the same conditions as described in Fig. 2e apart 
from the determination of the chromosomal morphologies, which was highlighted by staining with 0.2 μ M SiR‑DNA. Digital images were taken 
after 20 h incubation for quantification of the mitotic (g), apoptotic (h), and slippage indices (i). n: The number of the parallel experiments and the 
total cell numbers used for quantification. P value * < 0.026, 0.029, and 0.036 respectively
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cell dies in mitosis or exits and returns to interphase [20, 
34, 45]. Our results, however, suggest that in HeLa cells 
under the current experimental conditions, the accu-
mulation of Cyclin B1 with a reduced MCL-1 would not 
trigger apoptosis; moreover, an elevated MCL-1 and low-
ered Cyclin B1 would not directly trigger slippage either 
(Figs. 1, 2, 3, 6, 8). More interestingly, M2I-1 in the pres-
ence of nocodazole or taxol could induce cell death in 
cells with a low level of Cyclin B1 and stabilized MCL-1 
under a weakened SAC (Figs.  1, 3, 6, 8). This phenom-
enon cannot be explained by the “competing-networks” 
model [20]. Most likely, the premature degradation of 
Cyclin B1 caused by the M2I-1 treatment throughout the 
cell cycle combined with the microtubule network dis-
ruption caused by nocodazole or taxol reduced the cells 
fitness. The increased levels of the pro-apoptotic proteins 
MCL-1s and NOXA antagonized the pro-survival func-
tion of MCL-1 and triggered cells into undergoing apop-
tosis (Figs. 8, 9).
Conclusion
We have shown that as a single agent M2I-1 cannot cause 
cancer cell death, but it can significantly increase many 
cancer cells sensitivity to anti-mitotic drugs, such as noc-
odazole and taxol within the same cell cycle. This might 
prove to be significant, as it would increase the clinical 
efficacies of current drugs such as taxanes, epothilones, 
and vinca alkaloids and potentially reduce the length of 
treatment as well as the dose used. It might also slow 
any developing resistances and the possibility of relapse 
or new tumorigenesis after chemotherapy using current 
anti-mitotic drugs, though this has yet to be tested. We 
have also discovered some important molecular mecha-
nisms for understanding the relationships between the 
mitotic checkpoint and programmed cell death.
Materials and methods
Antibodies and reagents
Primary antibodies used in this project are Rabbit poly-
clonal anti-CDC20 antibody (Abcam, ab26483); mouse 
monoclonal anti-p55 CDC (E-7) (Santa Cruz Biotech, 
sc-13162); rabbit polyclonal anti-full length MAD2 (Con-
vance, PRB-452C); mouse monoclonal anti-cyclin B1 
(GNS) (Santa Cruz, sc-245); mouse monoclonal anti-
cyclin A (B-8) (Santa Cruz, sc-271682); mouse mono-
clonal anti-actin antibody (Abcam, ab6276); mouse 
monoclonal anti-GADPH antibody (Thermo Fisher Sci-
entific, MA5-15738); rabbit polyclonal anti-caspase-3 
antibody (Abcam, ab32351); rabbit polyclonal anti-
phospho-histone 3 (S-10) antibody (Millipore, #06-
570); and rabbit polyclonal anti-GFP antibody [Santa 
Cruz, sc-8334 (GP-FL)]; rabbit polyclonal anti-γ-H2AX 
(S-139) antibody (Abcam, ab-2893); GFP-Trap A geta-20 
(ChromoTek, 70112001A); rabbit polyclonal anti-Mcl-1 
(S-19) antibody (Santa Cruz, sc-819); rabbit polyclonal 
anti-pericentrin 1&2 antibody (Abcam, ab4448); rab-
bit polyclonal anti-BID (FL-195) antibody (Santa Cruz, 
sc-11423); mouse monoclonal anti-BIM (H-5) antibody 
(Santa Cruz, sc-374358); rabbit polyclonal anti-NOXA 
(FL-54) antibody (Santa Cruz, sc-30209) and monoclonal 
a b
Fig. 9 Ectopically expressed mGFP‑MCL‑1s sensitizes the MCF‑7 cells to M2I‑1 in the presence of nocodazole. a Western blot results showing the 
expression levels of PARP‑1F (full length) and its cleaved fragment PARP‑1C, MCL‑1, MCL‑1s and the exogenous GFP‑MCL‑1s. GAPDH was used 
as the loading control. b The quantification of the cleaved PARP‑1C under the experimental condition used in a. Data was quantified from three 
independent experiments after being normalised with the loading control. Paired t test. P value: * < 0.014
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anti-PUMA (G-3) antibody (Santa Cruz, sc-374223); rab-
bit monoclonal anti-human PARP-1 antibody (46D11) 
(Cell Signaling Technology).
Secondary antibodies goat polyclonal secondary 
antibody to rabbit IgG-H + L (DyLight 488) (Abcam, 
ab96899), goat anti-rabbit polyclonal IgG-H&L (Cy5), 
pre-adsorbed (Abcam, ab6564), IRDye 680 donkey 
anti-mouse (926–322227; LI-COR Biosciences), and 
IRDye 800CW donkey anti-mouse (926–32212; LI-COR 
Biosciences).
Duolink reagents Duolink In Situ PLA probe anti-Rab-
bit PLUS, Duolink In Situ PLA probe anti-Mouse Minus, 
Duolink In  Situ Detection Reagents Red (the Duolink 
assay reagent kits are distributed by Sigma-Aldrich).
Chemicals M2I-1 (ChemBridge Corporation), Cel-
Lytic™ MT Cell Lysis Reagent (Sigma-Aldrich, C3228), 
Protease inhibitor cocktail (Sigma-Aldrich, p8340), 
Thymidine (Sigma-Aldrich, Cas-358801), Nocodazole 
(Sigma-Aldrich, Cas-31430-18-9), Taxol (Paclitaxel, 
T7402) (Sigma-Aldrich), VP16 (etoposide) (Sigma-
Aldrich, E1383), DMEM (Sigma-Aldrich), DAPI (4′, 
6-Diamidine-2′-phenylindole dihydrochloride) (Sigma-
Aldrich, D9542), DMSO (Dimethylsulfoxide, Santa Cruz, 
sc-358801). Odyssey blocking solution (Li_Cor Bio-
sciences UK Ltd). SiR-DNA and Verapamil (Tebu-Bio).
Plasmid DNA and cell transfection
The original pcDNA3-flag-MCL-1s (human) was kindly 
provided as a gift by Professor Jeehyeon Bae’s lab at 
Chung-ANG university of South Korea. The plasmid 
DNA was used as a template for PCR (polymerase chain 
reaction) to generate the MCL-1s DNA fragment incor-
porated with Sgf1 and Mul1 restriction enzyme sites 
at its 5′ and 3′ ends respectively. This PCR fragment of 
Sgf1-MCL-1(s)-Mul1 was subsequently subcloned into 
a mammalian expression vector, pCMV6-AN-mGFP, at 
Sgf1 and Mul1 sites, in frame with and downstream of the 
mGFP sequence. The primer pair used for MCL-1s PCR, 
was 5′ forward: GAA TTC GCG ATC GCC ATG TTT GGC 
CTC AAA AGA AAC GC and 3′ reverse: GAA TTC ACG 
CGT TCA CAG TAA GGC TAT CTT ATT AGA TATGC.
The plasmid DNA transfections were performed using 
the LipofectamineTM3000 kit (ThermoFisher Scien-
tific, UK) according to the commercial protocol. Briefly, 
MCF-7 cells were grown in a T75 flask with 14 ml of an 
antibiotic-free DMEM medium up to 70% confluence. 
1  µg/ml of pCMV6-AN-mGFP-MCL-1s plasmid DNA 
was used for transfection. The solution containing the 
DNA lipid complex was added to MCF-7 cells for incuba-
tion at 37 °C supplied with 5%  CO2 for 24 h. The trans-
fected cells were harvested and resuspended in 12  ml 
of fresh complete medium and were split equally and 
seeded into 6 wells of a 6-well plate. The cells were used 
for drug treatment after all of them attached to the wells, 
which normally took about 6–8 h.
Cell culture conditions and treatments
The HeLa cell line overexpressing histone 2B-GFP, A549, 
HT29, U2OS and the RPE1CCNB1-Venus cells (a gift 
from Jonathan Pines’ lab, RPE1, a human retinal pig-
ment epithelial cell line) was cultured in DMEM medium 
(Dulbecco’s Modified Eagle Medium) as described before 
[6]. Cells were treated with 30  nM Taxol [34], 10  μM 
VP16, and 60 ng/ml (equivalent to 200 nM) nocodazole 
[5] or with 50 µM M2I-1 [27], or M2I-1 and nocodazole 
together in 0.5% DMSO for the lengths of time discussed 
in the results. Subsequently the treated or untreated 
HeLa cells were fixed using 1  ml cold (− 20  °C) metha-
nol [8] and left at room temperature for 5 min, or were 
fixed with 1 ml of 4% formamide-PBS (phosphate-buffer 
saline) solution for 10 min at room temperature and then 
stored at − 20  °C for later use. Cell extracts prepared 
using the same drug treatments but with increased cul-
ture volumes were used for western blotting.
Protein gel and western blotting
The cell extracts for gel electrophoresis, and western 
blotting were prepared as described before [6]. Cells 
were lysed in an appropriate amount of CelLytic™  MT 
Cell Lysis Reagent containing 1 × protease inhibitor 
cocktail on ice with agitation for 30  min. Samples of 
the cell lysates were separated using a precast 10% Bis–
Tris SDS-PAGE gel (sodium dodecyl sulfate polyacryla-
mide  gel  electrophoresis), and were then transferred 
onto a nitrocellulose membrane for western blotting. The 
membranes were blocked in 1x Odyssey blocking solu-
tion for 1  h and then probed with appropriate primary 
antibodies in Odyssey blocking solution (1:500 dilution) 
at room temperature for 2 h or at 4 °C overnight with agi-
tation. The membrane was then incubated with a second-
ary antibody solution of IRDye 680 donkey anti-mouse, 
or IRDye 800CW donkey anti-mouse, at 1:2000 dilutions 
for one and a half hours. The fluorescence signals were 
detected using a CCD scanner (Odyssey; LI-COR Bio-
sciences) according to the manufacturer’s instructions.
Immunofluoresence for γ‑H2AX
HeLa cells on a coverslip prepared as described above 
were washed three times in 1× PBS, and blocked with 
a blocking solution of 5% BSA (bovine serum albumin) 
in 1xPBS for an hour at room temperature followed by 
incubation with a primary mouse anti-human γ-H2AX 
antibody at a dilution of 1:500 in blocking solution. 
The cells were incubated overnight at 4  °C. Cells were 
washed twice in 1× PBS and once with 1× PBST (1× 
PBS + 0.1% Tween-20), for 5 min each. This was followed 
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by incubation with a Cy5 goat anti-mouse IgG secondary 
antibody at a dilution of 1:500 in blocking solution con-
taining an appropriate amount of DAPI at room tempera-
ture for 90 min in the dark. After being washed twice in 
1× PBS, and once with 1× PBST and air-dried as above 
the cells on the coverslips were mounted with an appro-
priate amount of 50% glycerol-PBS solution and sealed 
using nail vanish for later use.
PLA fluorescent immunostaining
The Duolink based proximity ligation assay (PLA) was 
conducted as described previously [6] with the follow-
ing changes. The paired primary antibodies used were a 
mouse monoclonal anti-Cyclin B1 and a rabbit polyclonal 
anti-Cyclin B1 (H-433).
Confocal imaging and quantification of the fluorescent 
complexes
The stained HeLa cells were scanned using a Leica TCS 
SP2 laser scanning confocal system same as described 
before [6].
The live images of the histone 2B-GFP in HeLa cells or 
MCF-7 cells stained with 0.2  μM SiR-DNA to illustrate 
the chromosome morphologies were recorded using a 
Nikon A1R fully automated high-speed confocal imaging 
system with a time interval of 5 min over 24 h.
ImageJ, Photoshop, and NIS-elements were used for 
quantification, editing of the fluorescent intensities of the 
complex or live imaging processing where appropriate.
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